Koji Izutsu
Director, Department of Hematology
National Cancer Center Hospital · Tokyo, Japan
Leads hematology at Japan's National Cancer Center. Key contributor to Japanese MCL treatment guidelines and clinical trials.
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.
The Lancet. Haematology · May 1, 2026
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis.
Current medical research and opinion · Dec 1, 2025
Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.
International journal of clinical oncology · Nov 1, 2025
Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma.
International journal of clinical oncology · Feb 1, 2024
Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post-marketing surveillance.
International journal of hematology · Feb 1, 2024